Kura Oncology announced positive topline results from a phase II trial for tipifarnib in patients with HRAS mutant relapsed or refractory squamous cell carcinomas of the head and neck. The phase II trial achieved its primary endpoint prior to the completion of enrollment.
Data from the phase Ib/II OrigAMI-4 study found that first-line treatment with investigational subcutaneous amivantamab and hyaluronidase-lpuj in combination with a PD-1 inhibitor delivered clinically meaningful and durable antitumor activity in patients with head and neck squamous cell carcinoma that is recurrent or metastatic, PD-L1-positive, and HPV-unrelated.Â
